Mira Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Mira Pharmaceuticals, Inc. filed a Form 8-K dated December 1, 2023, under Item 5.02 to report changes to its board and committee leadership. The company is incorporated in Florida, trades under the symbol MIRA on the Nasdaq Capital Market, and identifies as an emerging growth company.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It is limited to corporate governance matters.
Material Changes
- Michael Jerman was appointed Chairman of the Audit Committee effective December 1, 2023. He had previously joined the Audit Committee on November 14, 2023.
- Brian Daly resigned from the Board of Directors on December 1, 2023. He had served as Chairperson of the Audit Committee and as a member of the Compensation Committee.
- The company stated that Mr. Daly’s resignation did not result from any disagreement with the company, management, or the Board regarding operations, policies, or practices.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, contingencies, or risk updates. The principal disclosed item is the change in Audit Committee leadership following Mr. Daly’s resignation.
Facts Investors Should Verify
- Confirm the updated composition and independence of the Board and Audit Committee.
- Review subsequent filings for any additional director appointments or committee changes.
- Consult the company’s latest periodic report for financial condition, liquidity, cash runway, and operating results, none of which are provided in this filing.